Heterotopic ossification after the use of commercially available recombinant human bone morphogenetic proteins in four patients.
Heterotopic ossification occurring after the use of commercially available bone morphogenetic proteins has not been widely reported. We describe four cases of heterotopic ossification in patients treated with either recombinant bone morphogenetic protein 2 or recombinant bone morphogenetic protein 7. We found that while some patients were asymptomatic, heterotopic ossification which had occurred around a joint often required operative excision with good results.
Axelrad
T W
TW
Boston University Medical Center, Boston, Massachusetts 02118, USA.
Steen
B
B
Lowenberg
D W
DW
Creevy
W R
WR
Einhorn
T A
TA
D000328:Adult; D001857:Bone Matrix / Q000601:surgery; D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7 / Q000009:adverse effects*; D052004:Bone Morphogenetic Protein Receptors / Q000378:metabolism; D019485:Bone Morphogenetic Proteins / Q000009:adverse effects*; D005260:Female; D006801:Humans; D006810:Humeral Fractures / Q000000981:diagnostic imaging / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009999:Ossification, Heterotopic / Q000000981:diagnostic imaging / Q000209:etiology* / Q000601:surgery; D011183:Postoperative Complications / Q000209:etiology* / Q000601:surgery; D011859:Radiography; D011994:Recombinant Proteins / Q000009:adverse effects*; D016212:Transforming Growth Factor beta / Q000009:adverse effects*; D016896:Treatment Outcome
D055396:Bone Morphogenetic Protein 2; D055419:Bone Morphogenetic Protein 7; D019485:Bone Morphogenetic Proteins; D011994:Recombinant Proteins; D016212:Transforming Growth Factor beta; C499469:recombinant human bone morphogenetic protein-2; D052004:Bone Morphogenetic Protein Receptors